Income Statement
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $83K | — | -67.4% |
| SG&A Expense | $47K | — | -39.4% |
| Interest Expense | $0 | — | -100.0% |
| Net Income | -$4.3M | — | -60.9% |
| EPS (Basic) | -$0.10 | — | +23.1% |
| EPS (Diluted) | -$0.10 | — | +23.1% |
Balance Sheet
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.4M | -69.4% | -64.6% |
| Short-term Investments | $13.2M | -13.5% | — |
| Current Assets | $18.2M | -9.6% | — |
| Total Assets | $26.3M | -7.2% | — |
| Current Liabilities | $3.5M | +14.5% | — |
| Total Liabilities | $3.9M | +12.2% | — |
| Stockholders' Equity | $22.4M | -9.9% | +593.1% |
Cash Flow
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.0M | — | -137.4% |
| Investing Cash Flow | $1.5M | — | +127.8% |
| Financing Cash Flow | $0 | — | -100.0% |